Abstract
EBV associated disease continues to be a problem in the post-BHT population. The pathogenesis, risk factors, and diagnosis of PTLD, as well as the rationale, efficacy and advantages/disadvantages of various prophylactic, pre-emptive and treatment strategies are discussed.
MeSH terms
-
Blood Transfusion*
-
Bone Marrow Transplantation / immunology*
-
Epstein-Barr Virus Infections / immunology*
-
Humans
-
Immunosuppression Therapy
-
Immunotherapy, Adoptive
-
Lymphoproliferative Disorders / immunology
-
Lymphoproliferative Disorders / therapy
-
Lymphoproliferative Disorders / virology*
-
Risk Factors